Vaxart (NASDAQ:VXRT) Posts Earnings Results, Beats Expectations By $0.05 EPS

Vaxart (NASDAQ:VXRT) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05, Zacks reports. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.

Vaxart Trading Down 2.8 %

Shares of NASDAQ:VXRT opened at $0.57 on Friday. The business has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.71. Vaxart has a 1 year low of $0.45 and a 1 year high of $1.41. The firm has a market cap of $129.14 million, a price-to-earnings ratio of -1.38 and a beta of 1.69.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.